Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX

Lexicon Pharmaceuticals — Q3 2026 Earnings Presentation

19 slides from Lexicon Pharmaceuticals's earnings presentation, Nov 5, 2026

  1. Slide 1: Third Quarter 2026 Earnings

    Third Quarter 2026 Earnings Nove mber 5, 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr

  3. Slide 3: Q3 2026 Highlights

    Q3 2026 Highlights Mike Exton Ph.D. Director and Chief Executive Officer 3

  4. Slide 4: Year-to-Date 2026 Highlights

    Overview Year-to-Date 2026 Highlights Advancing our pipeline of novel therapies for serious cardiometabolic diseases SOTAGLIFLOZIN LX9851 PILAVAPADIN HCM T1D Heart Failure — Obesity Diabetic Peripheral Global Expansion Neuropathic Pain - Phase 3 SONATA- - STENO1 (third- - Phase 1 study HCM enrollmen

  5. Slide 5: Sotagliflozin in HCM

    Sotagliflozin in HCM Improving cardiac metabolism in HCM by working directly on the heart Enabled by unique SGLT1 mechanistic benefits Many presentations… nHCM one disease oHCM HYPERTROPHIC CARDIOMYOPATHY Characterized by global or The hallmark of Without With localized thickening Obstruction Obstru

  6. Slide 6: Significant Need Remains for Patients with HCM

    Sotagliflozin in HCM Significant Need Remains for Patients with HCM >800K ~2/3 SAFE + SIMPLE diagnosed HCM patients of symptomatic patients Strong need for an option that in the U.S.1 are nHCM – many more is safe with simple dosing remain undiagnosed2 POPULATION MOMENTUM TREATMENT GAP ACCESS BARRIER

  7. Slide 7: Pipeline Updates

    Pipeline Updates Craig Granowitz, M.D. Ph.D. Senior Vice President and Chief Medical Officer 7

  8. Slide 8: SONATA-HCM Phase 3 Study for Symptomatic HCM

    Sotagliflozin in HCM SONATA-HCM Phase 3 Study for Symptomatic HCM Baseline characteristics reflect broad and clinically relevant HCM population Enrollment Complete; Topline Results Q1 2027 • Patient demographics consistent with prior studies of Sotagliflozin 400 mg other agents in HCM and reflect re

  9. Slide 9: Growing Body of Recent Evidence Supports Sotagliflozin in HCM

    Sotagliflozin in HCM Growing Body of Recent Evidence Supports Sotagliflozin in HCM Highlights differentiation of dual inhibition compared to SGLT2 alone PRECLINICAL BIOLOGY CLINICAL READTHROUGH HCM CLINICAL PROGRAM AHA 2026 – To Be Presented | University of J Mol Cell Cardiol Plus 2026 | HCM Society

  10. Slide 10: Clinical Data Support ZYNQUISTA's Resubmission

    Sotagliflozin in T1D Clinical Data Support ZYNQUISTA’s Resubmission Patient-years of exposure achieved; DKA rates support positive benefit:risk profile inTandem clinical program STENO1 investigator-initiated study FDA-RECOGNIZED OUTCOMES IN T1D FDA RESUBMISSION CRITERIA ACHIEVED 1 HbA1c reduction 1

  11. Slide 11: STENO1 DKA Rates are Low and Comparable to Standard of Care

    Sotagliflozin in T1D STENO1 DKA Rates are Low and Comparable to Standard of Care ENROLLMENT SNAPSHOT Randomized patients, DKA rate per Group n 100 patient years Historic Rate in Denmark T1D Patients1 n/a ~1.0 Sotagliflozin 496 ~1.0 Standard of Care 708 ~1.0 Enrollment Summary as of August 30, 2026 N

  12. Slide 12: Pilavapadin Significant Reduction in Body Weight from Baseline

    Pilavapadin Significant Reduction in Body Weight from Baseline, Alone and in Combination With Semaglutide % Body Weight Change vs Vehicle 10 0 Pilavapadin drove a 13.9% % Body weight -10 -13.93% reduction alone -20 -25.51% Combined with -30 semaglutide, -40 -31.14% body-weight 0 4 7 11 14 18 21 25 2

  13. Slide 13: Financial Overview

    Financial Overview Scott Coiante Chief Financial Officer 13

  14. Slide 14: Q3 2026 Financial Summary

    Financials Q3 2026 Financial Summary $ (in millions except per share amounts) As of As of Q3 2026 Q3 2025 September 30, December 31, 2026 2025 Total revenues $11.3 $14.2 Cash, cash equivalents, short- $183.2 $125.2 R&D ($16.2) ($18.8) term investments and restricted cash SG&A ($9.5) ($7.6) Total ope

  15. Slide 15: Q3 2026 Financial Highlights and FY 2026 Guidance

    Financials Q3 2026 Financial Highlights and FY 2026 Guidance Q3 2026 Key Full Year 2026 Guidance Financial Highlights Operating Expenses* • Recognized $11.3 million in total revenue • Total 2026 operating expenses expected to be between • Includes third $10 million payment from Novo $100 - $110 mill

  16. Slide 16: Summary

    Summary Mike Exton Ph.D. Director and Chief Executive Officer 16

  17. Slide 17: Lexicon is Well Positioned for a Transformational Next 12 Months

    Conclusion Lexicon is Well Positioned for a Transformational Next 12 Months • Pivotal Phase 3 readout Q1 2027 • Potential broad HCM label path OUR HCM 01 SOTAGLIFLOZIN HEART FAILURE • Pre-commercial planning and readiness ongoing • Ex-U.S. HF launch progressing VISION • NDA resubmission anticipated

  18. Slide 18: Q&A

    Q&A Mike Exton, Ph.D. Craig Granowitz, M.D., Ph.D. Scott Coiante Director and Chief Senior Vice President Senior Vice President and Executive Officer and Chief Medical Officer Chief Financial Officer

  19. Slide 19: Thank You

    THANK YOU pharmaceuticals

Lexicon Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix